Allergic Rhinitis
Conditions
Interventions
Maxicurvi Yeast Live Bacteria Group:Maxicurvi yeast live bacteria powder, containing 5×10^9 CFU/g of yeast, 2g/day
Maxicurvi Yeast Inactivated Bacteria Group:Maxicurvi yeast inactivated bacteria powder, with yeast content of 5×10^9 CFU/g before inactivation, 2g/day
Placebo Group:Maltodextrin, 2g/day
Sponsors
West China Fourth Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18–60 years (inclusive). 2. Patients with perennial allergic rhinitis (PAR) who meet the diagnostic criteria of the "Chinese Guidelines for Diagnosis and Treatment of Allergic Rhinitis (2022, Revised Edition)", (1) with predominant allergens such as dust mites, moulds, and animal dander, and (2) with a positive skin prick test (SPT) (wheal mean diameter at least 3 mm larger than the negative control). 3. With or without concomitant symptoms of other allergic diseases (e.g., allergic rash, asthma, etc.). 4. Willing to participate in this study and sign the informed consent form. 5. During a 1-week run-in period, the subject's daily completion rate of the CSMS diary card is >80%.
Exclusion criteria
Exclusion criteria: 1.Subjects who have taken antibiotics recently, or regularly used immunosuppressants, probiotics, prebiotics and other agents that may interfere with trial results for a long time. 2.Patients diagnosed by a qualified physician with metabolic diseases such as diabetes, gout and hypertension, and/or severe organic diseases including heart disease. 3.Individuals with mental disorders. 4.Subjects with a history of gastrointestinal surgery. 5.Those who cannot guarantee residence in Chengdu for the next 2 months. 6.Presence of any nasal diseases that may interfere with the study results, including non-allergic rhinitis, chronic rhinosinusitis with or without nasal polyps, malignant or benign nasal tumors. 7.Subjects who received allergen-specific immunotherapy within the past 5 years, or plan to initiate such therapy during the study period. 8.Patients with seasonal allergic rhinitis, specifically those exclusively allergic to pollens such as sabina, paper mulberry and humulus scandens. 9.Asymptomatic subjects or those with extremely mild symptoms who required no medication in the past year and maintained a score of 0 on CSMS throughout the run-in period. 10.Any other conditions deemed ineligible by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total symptom score (TSS), Rhinoconjunctivitis Quality of Life Questionnaire(RQLQ) , Combined symptom-medication scores (CSMS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Gut Microbiota;Blood test indicators;Other immune markers (blood); | — |
Countries
China
Contacts
Public ContactShen Xi
West China Fourth Hospital of Sichuan University
Outcome results
None listed